184 related articles for article (PubMed ID: 10342987)
41. Medical-legal analysis and considerations in product liability cases involving pharmaceutical companies.
Woodside FC; Grunes AP; Comodeca JA
Leg Med; 1989; ():125-43. PubMed ID: 2700004
[No Abstract] [Full Text] [Related]
42. The perils of relying on interested parties to evaluate scientific quality.
Wagner W
Am J Public Health; 2005; 95 Suppl 1():S99-106. PubMed ID: 16030346
[TBL] [Abstract][Full Text] [Related]
43. Attorney abuses of Daubert hearings: junk science, junk law, or just plain obstruction?
Gutheil TG; Bursztajn HJ
J Am Acad Psychiatry Law; 2005; 33(2):150-2. PubMed ID: 15985655
[No Abstract] [Full Text] [Related]
44. Ten years of judicial gatekeeping under Daubert.
Cecil JS
Am J Public Health; 2005; 95 Suppl 1():S74-80. PubMed ID: 16030342
[TBL] [Abstract][Full Text] [Related]
45. The (near) irrelevance of Daubert to criminal justice and some suggestions for reform.
Neufeld PJ
Am J Public Health; 2005; 95 Suppl 1():S107-13. PubMed ID: 16030325
[TBL] [Abstract][Full Text] [Related]
46. The case against differential diagnosis: Daubert, medical causation testimony, and the scientific method.
Hollingsworth JG; Lasker EG
J Health Law; 2004; 37(1):85-111. PubMed ID: 15191237
[TBL] [Abstract][Full Text] [Related]
47. Task force 5: Expert testimony and opinions.
Bonow RO; Zipes DP; Anderson JL; Cheitlin MD; Goldstein LB; Grant AO; Faxon D; Lima JA; Robertson RM
J Am Coll Cardiol; 2004 Oct; 44(8):1747-9. PubMed ID: 15489119
[No Abstract] [Full Text] [Related]
48. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm.
Furrow BR
Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162
[No Abstract] [Full Text] [Related]
49. Expert medical testimony is generally required to prove medical negligence.
McCarter WD; Hayek TJ
Mo Med; 2001 Oct; 98(10):488-9. PubMed ID: 11668860
[No Abstract] [Full Text] [Related]
50. A critical examination of the post-Daubert scientific evidence landscape.
Kesan JP
Food Drug Law J; 1997; 52(2):225-51. PubMed ID: 10557562
[No Abstract] [Full Text] [Related]
51. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
Shea LL; Hanson A; Guglielmetti TM; Levy K
Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
[No Abstract] [Full Text] [Related]
52. Criteria for science in the courts.
Nature; 1993 Apr; 362(6420):481. PubMed ID: 8464481
[No Abstract] [Full Text] [Related]
53. Admissibility of neuropsychological testimony after Daubert and Kumho.
Stern BH
NeuroRehabilitation; 2001; 16(2):93-101. PubMed ID: 11568467
[TBL] [Abstract][Full Text] [Related]
54. Epidemiological evidence in forensic pharmacovigilance.
Persaud N; Healy D
Int J Risk Saf Med; 2012; 24(1):31-5. PubMed ID: 22436257
[TBL] [Abstract][Full Text] [Related]
55. Expert witness malfeasance: how should specialty societies respond?
Feld AD; Carey WD
Am J Gastroenterol; 2005 May; 100(5):991-5. PubMed ID: 15842567
[TBL] [Abstract][Full Text] [Related]
56. [No criminal liability of contract physicians for bribery].
Remmert J; Wigge P
Rofo; 2012 Dec; 184(12):1197-200. PubMed ID: 23212826
[No Abstract] [Full Text] [Related]
57. Tort liability and the availability of contraceptive drugs and devices in the United States.
Law SA
Rev Law Soc Change; 1997; 23(3):339-401. PubMed ID: 10725052
[No Abstract] [Full Text] [Related]
58. The weight of scientific evidence in policy and law.
Krimsky S
Am J Public Health; 2005; 95 Suppl 1():S129-36. PubMed ID: 16030328
[TBL] [Abstract][Full Text] [Related]
59. Should human figure drawings be admitted into court?
Lally SJ
J Pers Assess; 2001 Feb; 76(1):135-49. PubMed ID: 11206294
[TBL] [Abstract][Full Text] [Related]
60. Hemophilia. Judge puts limit on expert testimony from drug makers.
AIDS Policy Law; 1997 Jan; 12(1):5. PubMed ID: 12162262
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
